This inventor holds 1 USPTO granted patent. Top assignee: Oxford University Innovation Ltd. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Matthew B Avison: Innovator in β-lactamase Inhibitors
Introduction
Matthew B Avison is a prominent inventor based in Oxford, GB. He has made significant contributions to the field of medicine, particularly in the development of β-lactamase inhibitors. His work focuses on enhancing the effectiveness of antibiotics in treating tuberculosis and other infections.
Latest Patents
Matthew B Avison holds a patent for his invention related to β-lactamase inhibitors. The patent details the use of specific β-lactamase inhibitors in conjunction with one or more β-lactam antibiotics for the treatment of tuberculosis or infections. This innovation is crucial in combating antibiotic resistance and improving treatment outcomes.
Career Highlights
Matthew is associated with Oxford University Innovation Ltd, where he applies his expertise in research and development. His work has been instrumental in advancing medical treatments and addressing public health challenges.
Collaborations
He has collaborated with notable colleagues, including James Spencer and Christopher Joseph Schofield. These partnerships have fostered a collaborative environment that enhances innovation and research in the field.
Conclusion
Matthew B Avison is a key figure in the development of β-lactamase inhibitors, contributing to significant advancements in antibiotic treatment. His work exemplifies the importance of innovation in addressing critical health issues.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile